Neurotransmitter effects on tumor cells and leukocytes

Progress in Experimental Tumor Research

Volumn 39, Issue , 2007, Pages 99-121

  Lang, Kerstin ^a   Bastian, Philipp ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANIMAL; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; LEUKOCYTE; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; IMMUNE SYSTEM; LEUKOCYTES; NEOPLASMS; NEUROTRANSMITTER AGENTS;

EID: 33847418371     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000100070     Document Type: Review

References (188)

1. Berczi I, Chalmers IM, Nagy E, Warrington RJ: The immune effects of neuropeptides. Baillieres Clin Rheumatol 1996;10:227-257.
2. Felten DL: Direct innervation of lymphoid organs: substrate for neurotransmitter signaling of cells of the immune system. Neuropsychobiology 1993;28:110-112.
3. Lang K, Drell TL, Niggemann B, Zaenker KS, Entschladen F: Neurotransmitters regulate the migration and cytotoxicity in natural killer cells. Immunol Lett 2003;90:165-172.
4. Alaniz RC, Thomas SA, Perez-Melgosa M, Mueller K, Farr AG, Palmiter RD, Wilson CB: Dopamine beta-hydroxylase deficiency impairs cellular immunity. Proc Natl Acad Sci USA 1999;96:2274-2278.
5. Jiang XH, Guo SY, Xu S, Yin QZ, Ohshita Y, Naitoh M, Horibe Y, Hisamitsu T: Sympathetic nervous system mediates cold stress-induced suppression of natural killer cytotoxicity in rats. Neurosci Lett 2004;358:1-4.
6. Maestroni GJ: Adrenergic modulation of dendritic cells function: relevance for the immune homeostasis. Curr Neurovasc Res 2005;2:169-173.
7. Bastian P, Posch B, Lang K, Niggemann B, Zaenker KS, Hatt H, Entschladen F: Phosphatidylinositol 3-kinase in the G protein coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes. Mol Cancer Res 2006;4:411-421.
8. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D, Moots RJ: Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 2002;132:34-40.
9. Watanabe Y, Nakayama T, Nagakubo D, Hieshima K, Jin Z, Katou F, Hashimoto K, Yoshie O: Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. J Immunol 2006;176:848-856.
10. Sookhai S, Wang JH, Winter D, Power C, Kirwan W, Redmond HP: Dopamine attenuates the chemoattractant effect of interleukin-8: a novel role in the systemic inflammatory response syndrome. Shock 2000;14:295-299.
11. Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F: Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004;112:231-238.
12. Masur K, Lang K, Niggemann B, Zanker KS, Entschladen F: High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell 2001;12:1973-1982.
13. Palm D, Lang K, Niggemann B, Drell TL 4th, Masur K, Zaenker KS, Entschladen F: The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006;118:2744-2749.
14. Moriya T, Manabe T, Yamashita K, Arita S: Lung cancer metastasis to adrenocortical adenomas. A chance occurrence or a predilected phenomenon? Arch Pathol Lab Med 1988;112:286-289.
15. Miyaji N, Miki T, Itoh Y, Shimada J, Takeshita T, Churei H, Nakajo M: Radiotherapy for adrenal gland metastasis from lung cancer: report of three cases. Radiat Med 1999;17:71-75.
16. Hall WA, Djalilian HR, Nussbaum ES, Cho KH: Long-term survival with metastatic cancer to the brain. Med Oncol 2000;17:279-286.
17. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698-2705.
18. Masur K, Niggemann B, Zanker KS, Entschladen F: Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001;61:2866-2869.
19. Kohm AP, Sanders VM: Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 2001;53:487-525.
20. Hough LB: Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 2001;59:415-419.
21. Gutzmer R, Diestel C, Mommert S, Kother B, Stark H, Wittmann M, Werfel T: Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol 2005;174:5224-5232.
22. Seyedi N, Mackins CJ, Machida T, Reid AC, Silver RB, Levi R: Histamine H3-receptor-induced attenuation of norepinephrine exocytosis: a decreased protein kinase a activity mediates a reduction in intracellular calcium. J Pharmacol Exp Ther 2005;312:272-280.
23. Passani MB, Cangioli I, Baldi E, Bucherelli C, Mannaioni PF, Blandina P: Histamine H3 receptor-mediated impairment of contextual fear conditioning and in-vivo inhibition of cholinergic transmission in the rat basolateral amygdala. Eur J Neurosci 2001;14:1522-1532.
24. Prast H, Tran MH, Fischer H, Kraus M, Lamberti C, Grass K, Philippu A: Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H3 histamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999;360:558-564.
25. Schlicker E, Malinowska B, Kathmann M, Gothert M: Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol 1994;8:128-137.
26. Coge F, Guenin SP, Rique H, Boutin JA, Galizzi JP: Structure and expression of the human histamine H4-receptor gene. Biochem Biophys Res Commun 2001;284:301-309.
27. Falus A: Histamine, part of the metabolome. Acta Biol Hung 2003;54:27-34.
28. Tilly BC, Tertoolen LG, Remorie R, Ladoux A, Verlaan I, de Laat SW, Moolenaar WH: Histamine as a growth factor and chemoattractant for human carcinoma and melanoma cells: action through Ca2(+)-mobilizing H1 receptors. J Cell Biol 1990;110:1211-1215.
29. Valencia S, Hernandez-Angeles A, Soria-Jasso LE, Arias-Montano JA: Histamine H(1) receptor activation inhibits the proliferation of human prostatic adenocarcinoma DU-145 cells. Prostate 2001;48:179-187.
30. Ozdemir O: Mast cells and the tumor-associated neoangiogenesis comment to: Mast cells in neoangiogenesis Andrzej Nienartowicz, Maria E. Sobaniec-Lotowska, Elzbieta Jarocka-Cyrta, Dorota Lemancewicz: Med Sci Monit 2006;12:RA53-RA56.
31. Med Sci Monit 2006;12:LE9-L11.
32. Lesch KP, Mossner R: Inactivation of 5HT transport in mice: modeling altered 5HT homeostasis implicated in emotional dysfunction, affective disorders, and somatic syndromes. Handb Exp Pharmacol 2006;417-456.
33. Stahl SM: Neuroendocrine markers of serotonin responsivity in depression. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:655-659.
34. Mossner R, Lesch KP: Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 1998;12:249-271.
35. Idzko M, Panther E, Stratz C, Muller T, Bayer H, Zissel G, Durk T, Sorichter S, Di Virgilio F, Geissler M, Fiebich B, Herouy Y, Elsner P, Norgauer J, Ferrari D: The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J Immunol 2004;172:6011-6019.
36. O'Connell PJ, Wang X, Leon-Ponte M, Griffiths C, Pingle SC, Ahern GP: A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood 2006;107:1010-1017.
37. Boehme SA, Lio FM, Sikora L, Pandit TS, Lavrador K, Rao SP, Sriramarao P: Cutting edge: serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin. J Immunol 2004;173:3599-3603.
38. Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV: Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 2006;66:1136-1143.
39. Amorino GP, Parsons SJ: Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004;14:287-300.
40. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM: Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994;14:1215-1220.
41. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA: Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004;59:328-336.
42. Dizeyi N, Bjartell A, Hedlund P, Tasken KA, Gadaleanu V, Abrahamsson PA: Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol 2005;47:895-900.
43. Siddiqui EJ, Thompson CS, Mikhailidis DP, Mumtaz FH: The role of serotonin in tumour growth (review). Oncol Rep 2005;14:1593-1597.
44. Welsh JH: Composition and more of action of some invertebrate venoms. Annu Rev Pharmacol 1964;4:293-304.
45. Hinoi E, Takarada T, Tsuchihashi Y, Yoneda Y: Glutamate transporters as drug targets. Curr Drug Targets CNS Neurol Disord 2005;4:211-220.
46. Hyman SE: Addiction: a disease of learning and memory. Am J Psychiatry 2005;162:1414-1422.
47. Kalariti N, Pissimissis N, Koutsilieris M: The glutamatergic system outside the CNS and in cancer biology. Expert Opin Investig Drugs 2005;14:1487-1496.
48. McCluskey LP, Lampson LA: Local immune regulation in the central nervous system by substance P vs. glutamate. J Neuroimmunol 2001;116:136-146.
49. Stuckey DJ, Anthony DC, Lowe JP, Miller J, Palm WM, Styles P, Perry VH, Blamire AM, Sibson NR: Detection of the inhibitory neurotransmitter GABA in macrophages by magnetic resonance spectroscopy. J Leukoc Biol 2005;78:393-400.
50. Burgmeier N, Zawislak R, Defeudis FV, Bollack C, Helwig JJ: Glutamic acid decarboxylase in tubules and glomeruli isolated from rat kidney cortex. Eur J Biochem 1985;151:361-364.
51. Glassmeier G, Herzig KH, Hopfner M, Lemmer K, Jansen A, Scherubl H: Expression of functional GABAA receptors in cholecystokinin-secreting gut neuroendocrine murine STC-1 cells. J Physiol 1998;510(pt 3):805-814.
52. Jansen A, Hoepfner M, Herzig KH, Riecken EO, Scherubl H: GABA(C) receptors in neuroendocrine gut cells: a new GABA-binding site in the gut. Pflugers Arch 2000;441:294-300.
53. Joseph J, Niggemann B, Zaenker KS, Entschladen F: The neurotransmitter gamma-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res 2002;62:6467-6469.
54. Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F: Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003;80:63-70.
55. Entschladen F, Lang K, Drell TL, Joseph J, Zaenker KS: Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 2002;51:467-482.
56. Lang K, Drell TL, Niggemann B, Zanker KS, Entschladen F: Neurotransmitters regulate the migration and cytotoxicity in natural killer cells. Immunol Lett 2003;90:165-172.
57. Herpfer I, Lieb K: Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005;19:275-293.
58. Tuncer LI, Alacam T, Oral B: Substance P expression is elevated in inflamed human periradicular tissue. J Endod 2004;30:329-332.
59. Barnes PJ, Baraniuk JN, Belvisi MG: Neuropeptides in the respiratory tract. Part I. Am Rev Respir Dis 1991;144:1187-1198.
60. Kraneveld AD, Nijkamp FP: Tachykinins and neuro-immune interactions in asthma. Int Immunopharmacol 2001;1:1629-1650.
61. Joos GF, Germonpre PR, Pauwels RA: Role of tachykinins in asthma. Allergy 2000;55:321-337.
62. Kahler CM, Pischel A, Kaufmann G, Wiedermann CJ: Influence of neuropeptides on neutrophil adhesion and transmigration through a lung fibroblast barrier in vitro. Exp Lung Res 2001;27:25-46.
63. Carolan EJ, Casale TB: Effects of neuropeptides on neutrophil migration through noncellular and endothelial barriers. J Allergy Clin Immunol 1993;92:589-598.
64. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS: Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 2005;11:403-411.
65. Ruff M, Schiffmann E, Terranova V, Pert CB: Neuropeptides are chemoattractants for human tumor cells and monocytes: a possible mechanism for metastasis. Clin Immunol Immunopathol 1985;37:387-396.
66. Esteban F, Munoz M, Gonzalez-Moles MA, Rosso M: A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 2006;25:137-145.
67. Kanaide H, Ichiki T, Nishimura J, Hirano K: Cellular mechanism of vasoconstriction induced by angiotensin II: it remains to be determined. Circ Res 2003;93:1015-1017.
68. Contreras F, de la Parte MA, Cabrera J, Ospino N, Israili ZH, Velasco M: Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension. Am J Ther 2003;10:401-408.
69. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP: Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996;98:671-679.
70. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003;112:67-75.
71. Lever AF, Hole DJ, Gillis CR, McInnes GT, Meredith PA, Murray LS, Reid JL: Is cancer related to hypertension or to its treatment? Clin Exp Hypertens 1999;21:937-946.
72. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T: Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004;43:142-152.
73. Danilov SM, Sadovnikova E, Scharenborg N, Balyasnikova IV, Svinareva DA, Semikina EL, Parovichnikova EN, Savchenko VG, Adema GJ: Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol 2003;31:1301-1309.
74. Odaka C, Mizuochi T: Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clin Exp Immunol 2000;121:515-522.
75. Jankowski V, Vanholder R, van der Giet M, Henning L, Tolle M, Schonfelder G, Krakow A, Karadogan S, Gustavsson N, Gobom J, Webb J, Lehrach H, Giebing G, Schluter H, Hilgers KF, Zidek W, Jankowski J: Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension 2005;46:591-597.
76. Entschladen F, Bastian P, Niggemann B, Zaenker KS, Lang K: Inhibition of cell migration via G protein-coupled receptors to opioid peptides and angiotensin. Ann N Y Acad Sci 2004;1028:320-328.
77. Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE: Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension 2001;37:587-593.
78. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
79. Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659.
80. Sharma JN, Al-Dhalmawi GS: Bradykinin receptor antagonists: therapeutic implications. IDrugs 2003;6:581-586.
81. Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, Campos, MM: Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004;143:803-818.
82. Christopher J, Velarde V, Jaffa AA: Induction of B(1)-kinin receptors in vascular smooth muscle cells: cellular mechanisms of map kinase activation. Hypertension 2001;38:602-605.
83. Ehrenfeld P, Millan C, Matus CE, Figueroa JE, Burgos RA, Nualart F, Bhoola KD, Figueroa CD: Activation of kinin B1 receptors induces chemotaxis of human neutrophils. J Leukoc Biol 2006;80:117-124.
84. Stuardo M, Gonzalez CB, Nualart F, Boric M, Corthorn J, Bhoola KD, Figueroa CD: Stimulated human neutrophils form biologically active kinin peptides from high and low molecular weight kininogens. J Leukoc Biol 2004;75:631-640.
85. Wang H, Ehnert C, Brenner GJ, Woolf CJ: Bradykinin and peripheral sensitization. Biol Chem 2006;387:11-14.
86. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y: Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 2003;63:2037-2041.
87. Greco S, Elia MG, Muscella A, Romano S, Storelli C, Marsigliante S: Bradykinin stimulates cell proliferation through an extracellular-regulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture. J Endocrinol 2005;186:291-301.
88. Wang X, Fiscus RR, Yang L, Mathews HL: Suppression of the functional activity of IL-2-activated lymphocytes by CGRP. Cell Immunol 1995;162:105-113.
89. Mignini F, Streccioni V, Amenta F: Autonomic innervation of immune organs and neuroimmune modulation. Auton Autacoid Pharmacol 2003;23:1-25.
90. McGillis JP, Humphreys S, Rangnekar V, Ciallella J: Modulation of B lymphocyte differentiation by calcitonin gene-related peptide (CGRP). II. Inhibition of LPS-induced kappa light chain expression by CGRP. Cell Immunol 1993;150:405-416.
91. Foster CA, Mandak B, Kromer E, Rot A: Calcitonin gene-related peptide is chemotactic for human T lymphocytes. Ann N Y Acad Sci 1992;657:397-404.
92. Hosoi J, Murphy GF, Egan CL, Lerner EA, Grabbe S, Asahina A, Granstein RD: Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 1993;363:159-163.
93. Ahluwalia A, Perretti M: Calcitonin gene-related peptides modulate the acute inflammatory response induced by interleukin-1 in the mouse. Eur J Pharmacol 1994;264:407-415.
94. Gerbaud P, Segond N, Moukhtar MM, Evain-Brion D: Calcitonin and calcitonin gene-related peptide are chemotactic for F9 embryonal carcinoma cells. Endocrinology 1991;129:2530-2534.
95. Nagakawa O, Ogasawara M, Murata J, Fuse H, Saiki I: Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int J Urol 2001;8:65-70.
96. Wacnik PW, Baker CM, Herron MJ, Kren BT, Blazar BR, Wilcox GL, Hordinsky MK, Beitz AJ, Ericson ME: Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 2005;115:95-106.
97. Ribatti D, Nico B, Spinazzi R, Vacca A, Nussdorfer GG: The role of adrenomedullin in angiogenesis. Peptides 2005;26:1670-1675.
98. Zudaire E, Portal-Nunez S, Cuttitta F: The central role of adrenomedullin in host defense. J Leukoc Biol 2006;80:237-244.
99. Zudaire E, Martinez A, Cuttitta F: Adrenomedullin and cancer. Regul Pept 2003;112:175-183.
100. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R: Adrenomedullin and tumour angiogenesis. Br J Cancer 2006;94:1-7.
101. Cabot PJ: Immune-derived opioids and peripheral antinociception. Clin Exp Pharmacol Physiol 2001;28:230-232.
102. Cabot PJ, Carter L, Schafer M, Stein C: Methionine-enkephalin- and dynorphin A-release from immune cells and control of inflammatory pain. Pain 2001;93:207-212.
103. Rittner HL, Machelska H, Stein C: Leukocytes in the regulation of pain and analgesia. J Leukoc Biol 2005;78:1215-1222.
104. Rittner HL, Stein C: Involvement of cytokines, chemokines and adhesion molecules in opioid analgesia. Eur J Pain 2005;9:109-112.
105. Menzebach A, Hirsch J, Hempelmann G, Welters ID: Effects of endogenous and synthetic opioid peptides on neutrophil function in vitro. Br J Anaesth 2003;91:546-550.
106. Kirst A, Wack C, Lutz WK, Eggert A, Kampgen E, Fischer WH: Expression of functional kappa-opioid receptors on murine dendritic cells. Immunol Lett 2002;84:41-48.
107. Ichinose M, Asai M, Sawada M: Enhancement of phagocytosis by dynorphin A in mouse peritoneal macrophages. J Neuroimmunol 1995;60:37-43.
108. McCarthy LE, Nitsche JF, Pintar JE, Rogers TJ: The delta-opioid receptor participates in T-cell development by promoting negative selection. J Neuroimmunol 2004;153:91-98.
109. Sarkar A, Sreenivasan Y, Manna SK: Alpha-Melanocyte-stimulating hormone induces cell death in mast cells: involvement of NF-kappaB. FEBS Lett 2003;549:87-93.
110. Cooper A, Robinson SJ, Pickard C, Jackson CL, Friedmann PS, Healy E: Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol 2005;175:4806-4813.
111. Johnson EW, Hughes TK Jr, Smith EM: ACTH enhancement of T-lymphocyte cytotoxic responses. Cell Mol Neurobiol 2005;25:743-757.
112. Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ: Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol 2000;17:1053-1061.
113. Eves PC, MacNeil S, Haycock JW: Alpha-Melanocyte stimulating hormone, inflammation and human melanoma. Peptides 2006;27:444-452.
114. Zhu N, Lalla R, Eves P, Brown TL, King A, Kemp EH, Haycock JW, MacNeil S: Melanoma cell migration is upregulated by tumour necrosis factor-alpha and suppressed by alpha-melanocyte-stimulating hormone. Br J Cancer 2004;90:1457-1463.
115. Canton I, Eves PC, Szabo M, Vidal-Vanaclocha F, Sisley K, Rennie IG, Haycock JW, MacNeil S: Tumor necrosis factor alpha increases and alpha-melanocyte-stimulating hormone reduces uveal melanoma invasion through fibronectin. J Invest Dermatol 2003;121:557-563.
116. Sachs G, Zeng N, Prinz C: Physiology of isolated gastric endocrine cells. Annu Rev Physiol 1997;59:243-256.
117. Wank SA: G protein-coupled receptors in gastrointestinal physiology. I. CCK receptors: an exemplary family. Am J Physiol 1998;274:G607-G613.
118. Hur K, Kwak MK, Lee HJ, Park DJ, Lee HK, Lee HS, Kim WH, Michaeli D, Yang HK: Expression of gastrin and its receptor in human gastric cancer tissues. J Cancer Res Clin Oncol 2006;132:85-91.
119. Hirata M, Tsuchida A, Iwao T, Sasaki T, Matsubara K, Yamamoto S, Morinaka K, Kawasaki Y, Fujimoto Y, Inoue H, Kariya K, Kajiyama G: Cholecystokinin regulates the invasiveness of human pancreatic cancer cell lines via protein kinase C pathway. Int J Oncol 1999;14:1129-1135.
120. Sacerdote P, Ruff MR, Pert CB: Cholecystokinin and the immune system: receptor-mediated chemotaxis of human and rat monocytes. Peptides 1988;9(suppl 1):29-34.
121. Dumesny C, Whitley JC, Baldwin GS, Giraud AS, Shulkes A: Developmental expression and biological activity of gastrin-releasing peptide and its receptors in the kidney. Am J Physiol Renal Physiol 2004;287:F578-F585.
122. Preston SR, Miller GV, Primrose JN: Bombesin-like peptides and cancer. Crit Rev Oncol Hematol 1996;23:225-238.
123. Patel O, Shulkes A, Baldwin GS: Gastrin-releasing peptide and cancer. Biochim Biophys Acta 2006;1766:23-41.
124. Martinez A, Zudaire E, Julian M, Moody TW, Cuttitta F: Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene 2005;24:4106-4113.
125. Levine L, Lucci JA 3rd, Pazdrak B, Cheng JZ, Guo YS, Townsend CM Jr, Hellmich MR: Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003;63:3495-3502.
126. Bajo AM, Schally AV, Groot K, Szepeshazi K: Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer 2004;90:245-252.
127. Saurin JC, Fallavier M, Sordat B, Gevrey JC, Chayvialle JA, Abello J: Bombesin stimulates invasion and migration of Isrecol colon carcinoma cells in a Rho-dependent manner. Cancer Res 2002;62:4829-4835.
128. Zheng R, Iwase A, Shen R, Goodman OB, Sugimoto N, Takuwa Y, Lerner DJ, Nanus DM: Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. Oncogene 2006.
129. Makarenkova VP, Shurin GV, Tourkova IL, Balkir L, Pirtskhalaishvili G, Perez L, Gerein V, Siegfried JM, Shurin MR: Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J Neuroimmunol 2003;145:55-67.
130. Del Rio M, De la Fuente M: Chemoattractant capacity of bombesin, gastrin-releasing peptide and neuromedin C is mediated through PKC activation in murine peritoneal leukocytes. Regul Pept 1994;49:185-193.
131. De la Fuente M, Del Rio M, Hernanz A: Stimulation of natural killer and antibody-dependent cellular cytotoxicity activities in mouse leukocytes by bombesin, gastrin-releasing peptide and neuromedin C: involvement of cyclic AMP, inositol 1,4,5-trisphosphate and protein kinase C. J Neuroimmunol 1993;48:143-150.
132. Ebert R: Control of gastric emptying by regulatory peptides. Z Gastroenterol Verh 1988;23:165-170.
133. Hejna M, Hamilton G, Brodowicz T, Haberl I, Fiebiger WC, Scheithauer W, Virgolini I, Kostler WJ, Oberhuber G, Raderer M: Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract. Anticancer Res 2001;21:1183-1187.
134. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA: Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000;60:3105-3112.
135. Moody TW, Walters J, Casibang M, Zia F, Gozes Y: VPAC1 receptors and lung cancer. Ann N Y Acad Sci 2000;921:26-32.
136. Goursaud S, Pineau N, Becq-Giraudon L, Gressens P, Muller JM, Janet T: Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor. J Neuroimmunol 2005;158:94-105.
137. Sastry KS, Smith AJ, Karpova Y, Datta SR, Kulik G: Diverse anti-apoptotic signaling pathways activated by VIP, EGF and PI3K in prostate cancer cells converge on BAD. J Biol Chem 2006;281:20891-20901.
138. Sharma A, Walters J, Gozes Y, Fridkin M, Brenneman D, Gozes I, Moody TW: A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells. J Mol Neurosci 2001;17:331-339.
139. Moody TW, Dudek J, Zakowicz H, Walters J, Jensen RT, Petricoin E, Couldrey C, Green JE: VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice. Life Sci 2004;74:1345-1357.
140. Voice JK, Dorsam G, Chan RC, Grinninger C, Kong Y, Goetzl EJ: Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept 2002;109:199-208.
141. Huang MC, Miller AL, Wang W, Kong Y, Paul S, Goetzl EJ: Differential signaling of T cell generation of IL-4 by wild-type and short-deletion variant of type 2 G protein-coupled receptor for vasoactive intestinal peptide (VPAC2). J Immunol 2006;176:6640-6646.
142. Vassiliou E, Jiang X, Delgado M, Ganea D: TH2 lymphocytes secrete functional VIP upon antigen stimulation. Arch Physiol Biochem 2001;109:365-368.
143. Gonzalez-Rey E, Delgado M: Role of vasoactive intestinal peptide in inflammation and autoimmunity. Curr Opin Investig Drugs 2005;6:1116-1123.
144. Delgado M, Gonzalez-Rey E, Ganea D: VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J 2004;18:1453-1455.
145. Grimm MC, Newman R, Hassim Z, Cuan N, Connor SJ, Le Y, Wang JM, Oppenheim JJ, Lloyd AR: Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J Immunol 2003;171:4990-4994.
146. Foxx-Orenstein A, Camilleri M, Stephens D, Burton D: Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003;52:1555-1561.
147. Zaki M, Harrington L, McCuen R, Coy DH, Arimura A, Schubert ML: Somatostatin receptor subtype 2 mediates inhibition of gastrin and histamine secretion from human, dog, and rat antrum. Gastroenterology 1996;111:919-924.
148. Katz J: Acid secretion and suppression. Med Clin North Am 1991;75:877-887.
149. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C: Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001;47(suppl 2):30-39.
150. Ueberberg B, Tourne H, Redman A, Walz MK, Schmid KW, Mann K, Petersenn S: Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 2005;37:722-728.
151. Ferone D, van Hagen PM, Semino C, Dalm VA, Barreca A, Colao A, Lamberts SW, Minuto F, Hofland LJ: Somatostatin receptor distribution and function in immune system. Dig Liver Dis 2004;36(suppl 1):S68-S77.
152. Talme T, Ivanoff J, Hagglund M, Van Neerven RJ, Ivanoff A, Sundqvist KG: Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3. Clin Exp Immunol 2001;125:71-79.
153. Talme T, Ivanoff J, Sundqvist KG: Somatostatin is a specific inhibitor of SDF-1alpha-induced T cell infiltration. Clin Exp Immunol 2004;135:434-439.
154. Partsch G, Matucci-Cerinic M: Effect of substance P and somatostatin on migration of polymorphonuclear (PMN) cells in vitro. Inflammation 1992;16:539-547.
155. Watt HL, Kumar U: Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells. Cancer Cell Int 2006;6:5.
156. Kumar M, Liu ZR, Thapa L, Chang Q, Wang DY, Qin RY: Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro. World J Gastroenterol 2004;10:393-399.
157. Luscher TF, Barton M: Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434-2440.
158. Huang SC: Endothelin receptors in gastrointestinal smooth muscle. Curr Protein Pept Sci 2005;6:547-557.
159. Nelson J, Bagnato A, Battistini B, Nisen P: The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-116.
160. Rosano L, Spinella F, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A: Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med (Maywood) 2006;231:1128-1131.
161. Hagemann T, Binder C, Binder L, Pukrop T, Trumper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol 2005;24:766-776.
162. Cunningham ME, Huribal M, Bala RJ, McMillen MA: Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit Care Med 1997;25:958-964.
163. Grimshaw MJ, Wilson JL, Balkwill FR: Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol 2002;32:2393-2400.
164. Guruli G, Pflug BR, Pecher S, Makarenkova V, Shurin MR, Nelson JB: Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 2004;104:2107-2115.
165. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ: The non-neuronal cholinergic system in humans: expression, function and pathophysiology. Life Sci 2003;72:2055-2061.
166. Daly JW: Nicotinic agonists, antagonists, and modulators from natural sources. Cell Mol Neurobiol 2005;25:513-552.
167. Kawashima K, Fujii T: The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci 2003;74:675-696.
168. Kawashima K, Fujii T: The lymphocytic cholinergic system and its biological function. Life Sci 2003;72:2101-2109.
169. Qiu YH, Peng YP, Jiang JL, Wang JJ: Effect of acetylcholine on in vitro IL-2 production and NK cell cytotoxicity of rats. Lymphology 2004;37:31-38.
170. Iho S, Tanaka Y, Takauji R, Kobayashi C, Muramatsu I, Iwasaki H, Nakamura K, Sasaki Y, Nakao K, Takahashi T: Nicotine induces human neutrophils to produce IL-8 through the generation of peroxynitrite and subsequent activation of NF-kappaB. J Leukoc Biol 2003;74:942-951.
171. Lau PP, Li L, Merched AJ, Zhang AL, Ko KW, Chan L: Nicotine induces proinflammatory responses in macrophages and the aorta leading to acceleration of atherosclerosis in low-density lipoprotein receptor(-/-) mice. Arterioscler Thromb Vasc Biol 2006;26:143-149.
172. Czura CJ, Friedman SG, Tracey KJ: Neural inhibition of inflammation: the cholinergic antiinflammatory pathway. J Endotoxin Res 2003;9:409-413.
173. Lammerding-Koppel M, Noda S, Blum A, Schaumburg-Lever G, Rassner G, Drews U: Immunohistochemical localization of muscarinic acetylcholine receptors in primary and metastatic malignant melanomas. J Cutan Pathol 1997;24:137-144.
174. Williams CL: Muscarinic signaling in carcinoma cells. Life Sci 2003;72:2173-2182.
175. Song P, Sekhon HS, Proskocil B, Blusztajn JK, Mark GP, Spindel ER: Synthesis of acetylcholine by lung cancer. Life Sci 2003;72:2159-2168.
176. Ukegawa JI, Takeuchi Y, Kusayanagi S, Mitamura K: Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells. J Cancer Res Clin Oncol 2003;129:272-278.
177. Blanco M, Robinson MJ: Muscarinic M3 acetylcholine receptor immunostaining in paraffin-embedded normal and neoplastic prostatic gland tissue. Ann Diagn Pathol 2004;8:333-336.
178. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-613.
179. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
180. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
181. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M, Metters KM: Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 1995;48:352-361.
182. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H: The cannabinoid system and immune modulation. J Leukoc Biol 2003;74:486-496.
183. Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD: Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002;133:124-131.
184. Joseph J, Niggemann B, Zaenker KS, Entschladen F: Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 2004;53:723-728.
185. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V: Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000;141:118-126.
186. Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M, Caruso MG, Notarnicola M, Iacuzzo I, Portella G, Di Marzo V, Bifulco M: Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 2006;312:363-373.
187. Roth MD, Baldwin GC, Tashkin DP: Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 2002;121:229-239.
188. De Petrocellis L, Melck D, Bisogno T, Di Marzo V: Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 2000;108:191-209.